Jan 16 (Reuters) - GlaxoSmithKline PLC:
* GSK PRESENTS POSITIVE EFFICACY DATA OF DOSTARLIMAB IN MISMATCH REPAIR-DEFICIENT (DMMR) SOLID CANCERS AT ASCO GASTROINTESTINAL CANCERS SYMPOSIUM
* GSK-BIOLOGICS LICENSE APPLICATION, MARKETING AUTHORISATION APPLICATION FOR DOSTARLIMAB ARE CURRENTLY UNDER REVIEW BY US FDA & EUROPEAN MEDICINES AGENCY
* DATA FROM GARNET COHORT F SHOWS A 38.7% OBJECTIVE RESPONSE RATE WITH DOSTARLIMAB IN PATIENTS WITH DMMR ADVANCED SOLID CANCERS Source text : bit.ly/3ig0D6o Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.